

Micro-X Limited, ABN 21 153 273 735

CLOSE OF PROSPECTUS OFFER

Adelaide, Australia, 24 December 2019: Australian high-tech company Micro-X Ltd (ASX: MX1) (**Micro-X** or the **Company**) a leader in cold cathode x-ray technology for health and security markets globally, advises that it has today closed the Offer under the Prospectus lodged with the Australian Securities & Investments Commission (**ASIC**) and the ASX on 19 November 2019 (**Prospectus**).

As foreshadowed in the announcement of the \$16.5 million Private Placement on 19 November 2019, the Company lodged a transaction specific Prospectus with ASIC on 19 November 2019.

The Offer under the Prospectus was intended to remain open until 5pm ACDT on 31 January 2020 but as the Offer under the Prospectus has been fully subscribed, the directors have resolved to close the Offer on 24 December 2019.

Authorised by the board of Micro-X Limited.

Issued to ASX by Georgina Carpendale, Company Secretary and CFO.

- ENDS -

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the Carestream DRX Revolution Nano, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The Carestream DRX Revolution Nano holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for airport security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland	David Allen / John Granger
Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	Hawkesbury Partners
	Tel: +61 2 9103 9494
	E: dallen@hawkesburypartners.com
	jgranger@hawkesburypartners.com